Published in Cardiovascular Business Week, December 8th, 2009
"We conducted a post-hoc analysis to evaluate Hgb variability in 2 trials of EPO in CKD anemia; both examined Hgb response during dosing intervals up to 4 weeks. I examined 4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week